The Whiteway Lab

               Our ongoing research investigates the medically important fungal pathogen Candida albicans, with the ultimate goal of identifying new treatment options for patients suffering from Candida infections. We use an array of genetic and genomic approaches to investigate pathways involved in various C. albicans functions. As part of these efforts we collaborated with various international research teams in the assembly and annotation of the C. albicans genome.

                We are now using genome-based tools such as transcriptional profiling and ChIP-chip analysis to investigate regulatory circuits in the pathogen. We have identified dramatic cases of transcriptional rewiring of central metabolic pathways, synchronized cells and established the transcriptional profile of the C. albicans cell cycle, and investigated the regulation of the fungal mating system.

                We are also screening an extensive library of conditional C. albicans mutants using various physiological and chemical treatments through the Functional Genomics robotic facility at Concordia. This will allow us to explore, tailor, and understand the subtleties that make C. albicans a human pathogen.         

                                                               WHITEWAY LAB  2016            

Recent News

  • The Globe and Mail news article The Globe and Mail published an article (June 6, 2015) which summarizes our ongoing research highlighting importance of genomic studies and management of fungal disease in coming days. Click here ...
    Posted Aug 26, 2015, 10:39 AM by malcolm whiteway
  • Student research: Jacob Kantorowitz Jacob Kantorowitz, a third-year pharmacology major student from McGill University worked in the Whiteway lab studying Candida albicans and was in the news. Read the full story.
    Posted Aug 26, 2015, 10:37 AM by malcolm whiteway
  • PROFESSORS WILL USE FUNDS TO FIGHT FUNGUS AND UPDATE AIRCRAFT $2.8 million for Concordia University researchPROFESSORS WILL USE FUNDS TO FIGHT FUNGUS AND UPDATE AIRCRAFTPosted on November 14, 2013Montreal, November 14, 2013 — Thanks to new funding ...
    Posted Dec 3, 2013, 9:49 AM by malcolm whiteway
  • Concordia receives $943,000 for pathogen research original post from: Cléa DesjardinsPublished on January 7, 2013 MERCK CANADA INVESTS IN THE CENTRE FOR STRUCTURAL AND FUNCTIONAL GENOMICS Biomedical research at Concordia University has received a generous ...
    Posted Jan 14, 2013, 10:28 AM by Malcolm Whiteway
  • Concordia's Exposcience hooks West Island kids on science Thanks to Nick and Julien for helping out during Concordia's Exposcience. With more than 1 500 visitors, this 2 day event was a hit. This event was covered in ...
    Posted Dec 5, 2012, 6:24 AM by Malcolm Whiteway
Showing posts 1 - 5 of 9. View more »

Dr. Donald Sheppard's talk on Friday, January 16, 2015 at 1:15PM (ROOM: SP-S110) Loyola Campus.

Topic: Galactosaminogalactan - Development of therapeutic strategies targeting a mutivalent virulence factor of Aspergillus fumigatus.

Learn more about Dr. Sheppard's research.